A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
RecruitingCTIS2022-501895-25-00
Novartis Pharma AGPolymyalgia Rheumatica
Start: 2023-09-13Target: 233Updated: 2026-01-19